CKD and cardiometabolic
In nearly two million US adults in 2024, statin prescriptions were lower at more advanced stages of kidney disease, the opposite of how risk usually drives treatment. A baseline before the 2026 ACC/AHA guideline.
Trailer
Why I built NephSpace, in my own voice, plus three short moments from the show. Two minutes.
Deep Dive
Two dialysis patients, same city, same week. One gets a new machine that filters and replaces more than 20 liters every session. The other gets the same old machine with a new filter. Both are told it's the future. Hemodiafiltration has a survival trial but needs new machines. Medium cutoff…
Weekly
Two ways to clear more middle molecules arrive in US dialysis units at once. A urine dipstick can show whether patients are taking their SGLT2 inhibitor. Two papers disagree about who should let AI write the notes. Nine picks from the week of September 21, 2026, each with the story, the numbers…
Dialysis
Authors of the main hemodiafiltration trials explain how to prescribe high-volume HDF and predict it will likely become the global standard. Most of them have ties to HDF machine makers.
Dialysis
In a Healio Q&A, Dr. Jeffrey Giullian describes DaVita's switch to medium cutoff dialyzers and why he expects middle-molecule clearance to become standard care. Outcome data are still being gathered.
Glomerular disease
The approval covers patients from age 2, including adults whose disease began in childhood. Healio's report rests on a press release and does not yet give the trial's numbers.
CKD and cardiometabolic
The authors argue nephrology must move upstream into cardio-kidney-metabolic care, and that the AHA's CKM model undersells the kidney. If nephrologists stay out, CKD will be found more often but diagnosed less precisely.
CKD and cardiometabolic
A CJASN review explains why atherosclerosis runs hot in CKD, why chest pain and standard risk scores mislead, which treatments have evidence, plus an inflammation trial that missed.
CKD and cardiometabolic
A CJASN How I Treat case argues the barrier to GLP-1 receptor agonists in CKD is putting them into practice, not the evidence. It lays out titration, lab checks, insulin cuts and how to protect muscle.
CKD and cardiometabolic
In 45,711 patients newly prescribed an SGLT2 inhibitor, glucose on a routine dipstick went with lower mortality, heart failure hospitalization and kidney failure, while fractures didn't budge. The study is observational, but the check is free.
Other
Three Mayo Clinic authors map where AI could save time before, during and after a visit. Their first picks are chart summaries, message drafts and admin documents, though the evidence for those uses is still thin.